Medicare Part D Defining Cardiovascular Disease

This is a news story, published by EurekAlert!, that relates primarily to Medicare news.

News about health policy

For more health policy news, you can click here:

more health policy news

EurekAlert! news

For more news from EurekAlert!, you can click here:

more news from EurekAlert!

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about health policy, you might also like this article about

Medicare costs

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Medicare news, cardiovascular risk news, news about health policy, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

cardiovascular disease

EurekAlert!

•

Brigham-led study estimates 1 in 7 Medicare beneficiaries with high body mass index may qualify for anti-obesity drug

Summary

Nutrition label

91% Informative

If Medicare Part D narrowly defines cardiovascular disease, majority of patients would remain ineligible while new federal spending could still exceed $10 billion .

Semaglutide (Wegovy) is a popular glucagon-like peptide-1 receptor agonist (GLP-1RA) for patients with elevated body mass index ( BMI ) who also had established cardiovascular disease.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful